文献速递肿瘤 PET/CT

先进数字化PET/CT在肿瘤病灶检测中性能提升的获益

Benefit of Improved Performance with State-of-the Art Digital PET/CT for Lesion Detection in Oncology.
PubMed 文献 · J Nucl Med · 2020-03-20

该研究通过体模实验比较两代Biograph PET/CT(mCT Flow与Vision)对已知对比度病灶的检测能力,假设Vision的物理性能提升可改善病灶可检测性,从而缩短成像时间或降低注射剂量。结果显示Vision的ALROC明显高于mCT Flow,对直径至少9.89 mm的病灶,成像时间(或注射剂量)可减少4-6倍;更小病灶在mCT Flow中几乎无法检测,Vision的ALROC增益更大。Vision改善的空间分辨率使测得对比度更接近真实摄取,提示定量改善,但重建后平滑会削弱该对比度改善,从而降低小且高摄取病灶的ALROC。

要点

  • Vision的ALROC明显高于mCT Flow,对直径至少9.89 mm病灶,成像时间或注射剂量可减少4-6倍。
  • 更小病灶在mCT Flow中几乎无法检测,Vision的ALROC增益更大。
  • Vision改善的空间分辨率使测得对比度更高、更接近真实摄取,提示定量改善;重建后平滑会削弱该改善。

核心结论

  • Vision整体性能提升,对直径至少9.89 mm的病灶,按ALROC指标,成像时间(或注射剂量)较mCT Flow减少4-6倍。
  • 更小病灶在mCT Flow中几乎无法检测,Vision的ALROC增益更大。
  • Vision改善的空间分辨率使测得对比度更高、更接近真实摄取,提示定量改善;重建后平滑会削弱该对比度改善,从而降低小且高摄取病灶的ALROC。

研究设计与样本

  • 研究采用美国核医学与分子影像学会临床试验网络躯干体模,并结合直径20 cm圆柱体模获取数据。
  • 通过球体在空气中采集数据并与体模数据合并,生成嵌入已知对比度病灶的合并数据集。
  • 使用两种球体尺寸和摄取:直径9.89 mm球体局部活度浓度摄取为6:1(肺)和3:1(圆柱体);直径4.95 mm球体局部活度浓度摄取为9.6:1(肺)和4.5:1(圆柱体)。
  • 标准图像重建采用带点扩散函数和飞行时间建模的普通泊松有序子集期望最大化算法,重建后以5 mm高斯滤波器平滑;Vision图像也生成无重建后平滑的版本。
  • 采用广义扫描统计方法估计局部化受试者工作特征曲线下面积(ALROC)。

主要发现

  • Vision更高的灵敏度和改善的飞行时间性能导致背景噪声结节分布中对比度降低。
  • 由于空间分辨率改善,Vision上测得的病灶对比度也更高。
  • 因此,Vision的ALROC明显高于mCT Flow。
  • 对直径至少9.89 mm的病灶,按ALROC指标,Vision较mCT Flow的成像时间(或注射剂量)减少4-6倍。
  • 更小病灶在mCT Flow中几乎无法检测,导致Vision的ALROC增益更大;重建后平滑会降低小且高摄取病灶的ALROC。

关键数值与推荐

  • 直径9.89 mm球体局部活度浓度摄取:6:1(肺)和3:1(圆柱体)。
  • 直径4.95 mm球体局部活度浓度摄取:9.6:1(肺)和4.5:1(圆柱体)。
  • 图像重建后平滑采用5 mm高斯滤波器。
  • 对直径至少9.89 mm的病灶,Vision较mCT Flow的成像时间(或注射剂量)减少4-6倍(基于ALROC指标)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The latest digital whole-body PET scanners provide a combination of higher sensitivity and improved spatial and timing resolution. We performed a lesion detectability study on two generations of Biograph PET/CT scanners, the mCT Flow and the Vision, to study the impact of improved physical performance on clinical performance. Our hypothesis was that the improved performance of the Vision would result in improved lesion detectability, allowing shorter imaging times or, equivalently, a lower injected dose. Methods: Data were acquired with the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network torso phantom combined with a 20-cm-diameter cylindrical phantom. Spherical lesions were emulated by acquiring sphere-in-air data and combining them with the phantom data to generate combined datasets with embedded lesions of known contrast. Two sphere sizes and uptakes were used: 9.89-mm-diameter spheres with 6:1 (lung) and 3:1 (cylinder) local activity concentration uptakes and 4.95-mm-diameter spheres with 9.6:1 (lung) and 4.5:1 (cylinder) local activity concentration uptakes. Standard image reconstruction was performed: an ordinary Poisson ordered-subsets expectation maximization algorithm with point-spread function and time-of-flight modeling and postreconstruction smoothing with a 5-mm gaussian filter. The Vision images were also generated without any postreconstruction smoothing. Generalized scan statistics methodology was used to estimate the area under the localized receiver-operating-characteristic curve (ALROC). Results: The higher sensitivity and improved time-of-flight performance of the Vision leads to reduced contrast in the background noise nodule distribution. Measured lesion contrast is also higher on the Vision because of its improved spatial resolution. Hence, the ALROC is noticeably higher for the Vision than for the mCT Flow. Conclusion: Improved overall performance of the Vision provides a factor of 4-6 reduction in imaging time (or injected dose) over the mCT Flow when using the ALROC metric for lesions at least 9.89 mm in diameter. Smaller lesions are barely detected in the mCT Flow, leading to even higher ALROC gains with the Vision. The improved spatial resolution of the Vision also leads to a higher measured contrast that is closer to the real uptake, implying improved quantification. Postreconstruction smoothing, however, reduces this improvement in measured contrast, thereby reducing the ALROC for small, high-uptake lesions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Surti S, Viswanath V, Daube-Witherspoon ME, et al. Benefit of Improved Performance with State-of-the Art Digital PET/CT for Lesion Detection in Oncology. J Nucl Med. 2020. PMID: 32198313. doi:10.2967/jnumed.120.242305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。